Phosphodiesterase type 5 inhibitors: Back and forward from cardiac indications

Journal of Endocrinological Investigation

Volumn 39, Issue 2, 2016, Pages 143-151

  Corinaldesi, C ^a   Di Luigi, L ^a   Lenzi, A ^b   Crescioli, C ^a  

^a UNIVERSITY OF ROME FORO ITALICO   (Italy)

^b SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

Cardioprotection; Inflammation; PDE5 inhibitors

Indexed keywords

PHOSPHODIESTERASE V INHIBITOR; CARDIOVASCULAR AGENT; NONSTEROID ANTIINFLAMMATORY AGENT; PHOSPHODIESTERASE V; VASODILATOR AGENT;

CARDIOMYOPATHY; CELLULAR DISTRIBUTION; CORONARY ARTERY DISEASE; DRUG EFFICACY; DRUG MECHANISM; ERECTILE DYSFUNCTION; FIBROSIS; HEART DISEASE; HUMAN; INFLAMMATION; PULMONARY HYPERTENSION; REVIEW; TISSUE DISTRIBUTION; TREATMENT INDICATION; ANIMAL; CARDIAC MUSCLE; CARDIOVASCULAR DISEASES; CHEMISTRY; DRUG EFFECTS; ENZYMOLOGY; EVIDENCE BASED MEDICINE; HEART; HYPERTENSION, PULMONARY; IMMUNOLOGY; METABOLISM; PATHOPHYSIOLOGY; VASCULAR ENDOTHELIUM;

ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CARDIOVASCULAR AGENTS; CARDIOVASCULAR DISEASES; CORONARY ARTERY DISEASE; CYCLIC NUCLEOTIDE PHOSPHODIESTERASES, TYPE 5; ENDOTHELIUM, VASCULAR; EVIDENCE-BASED MEDICINE; HEART; HUMANS; HYPERTENSION, PULMONARY; MYOCARDIUM; PHOSPHODIESTERASE 5 INHIBITORS; VASODILATOR AGENTS;

EID: 84955265039     PISSN: 03914097     EISSN: 17208386     Source Type: Journal    
DOI: 10.1007/s40618-015-0340-5     Document Type: Review

References (97)

1. Conti M, Beavo J (2007) Biochemistry and physiology of cyclic nucleotide phosphodiesterases: essential components in cyclic nucleotide signaling. Annu Rev Biochem 76:481-511
2. Omori K, Kotera J (2007) Overview of PDEs and their regulation. Circ Res 100:309-327
3. Rao YJ, Xi L (2009) Pivotal effects of phosphodiesterase inhibitors on myocyte contractility and viability in normal and ischemic hearts. Acta Pharmacol Sin 30:1-24
4. Yan C, Miller CL, Abe J (2007) Regulation of phosphodiesterase 3 and inducible cAMP early repressor in the heart. Circ Res 100:489-501
5. Bender AT, Beavo JA (2006) Cyclic nucleotide phosphodiesterases: molecular regulation to clinical use. Pharmacol Rev 58:488-520
6. Kukreja RC, Ockaili R, Salloum F, Yin C, Hawkins J, Das A, Xi L (2004) Cardioprotection with phosphodiesterase-5 inhibition - a novel preconditioning strategy. J Mol Cell Cardiol 36:165-173
7. Rotella DP (2002) Phosphodiesterase 5 inhibitors: current status and potential applications. Nat Rev Drug Discovery 1:674-682
8. Glossmann H, Petrischor G, Bartsch G (1999) Molecular mechanisms of the effects of sildenafil (VIAGRA). Exp Gerontol 34:305-318
9. Beavo JA (1995) Cyclic nucleotide phosphodiesterases: functional implications of multiple isoforms. Physiol Rev 75:725-748
10. Teerlink JR, Metra M, Zacà V, Sabbah HN, Cotter G, Gheorghiade M, Cas LD (2009) Agents with inotropic properties for the management of acute heart failure syndromes. Traditional agents and beyond. Heart Fail Rev 14:243-253
11. Liu H, Maurice DH (1998) Expression of cyclic GMP-inhibited phosphodiesterases 3A and 3B (PDE3A and PDE3B) in rat tissues: differential subcellular localization and regulated expression by cyclic AMP. Br J Pharmacol 125:1501-1510
12. Gurney ME, D'Amato EC, Burgin AB (2014) Phosphodiesterase-4 (PDE4) molecular pharmacology and alzheimer's disease. Neurotherapeutics 12:49-56
13. Soderling SH, Bayuga SJ, Beavo JA (1998) Cloning and characterization of a cAMP-specific cyclic nucleotide phosphodiesterase. Proc Natl Acad Sci 95:8991-8996
14. Vang AG, Ben-Sasson SZ, Dong H, Kream B, DeNinno MP, Claffey MM, Housley W, Clark RB, Epstein PM, Brocke S (2010) PDE8 regulates rapid Teff cell adhesion and proliferation independent of ICER. PLoS One 5:e12011
15. Siuciak JA (2008) The role of phosphodiesterases in schizophrenia: therapeutic implications. CNS Drugs 22:983-993
16. Kelly MP, Logue SF, Brennan J, Day JP, Lakkaraju S, Jiang L, Zhong X, Tam M, Sukoff Rizzo SJ, Platt BJ, Dwyer JM, Neal S, Pulito VL, Agostino MJ, Grauer SM, Navarra RL, Kelley C, Comery TA, Murrills RJ, Houslay MD, Brandon NJ (2010) Phosphodiesterase 11A in brain is enriched in ventral hippocampus and deletion causes psychiatric disease-related phenotypes. Proc Natl Acad Sci 107:8457-8462
17. Lin CS, Lin G, Xin ZC, Lue TF (2006) Expression, distribution and regulation of phosphodiesterase 5. Curr Pharm Des 12:3439-3457
18. D'Amati G, di Gioia CR, Bologna M, Giordano D, Giorgi M, Dolci S, Jannini EA (2002) Type 5 phosphodiesterase expression in the human vagina. Urology 60:191-195
19. Dolci S, Belmonte A, Santone R, Giorgi M, Pellegrini M, Carosa E, Piccione E, Lenzi A, Jannini EA (2006) Subcellular localization and regulation of type-1C and type-5 phosphodiesterases. Biochem and Biophys Res Commun 341:837-846
20. Carosa E, Castri A, Forcella C, Sebastiani G, Di Sante S, Gravina GL, Ronchi P, Cesarini V, Dolci S, Di Stasi S, Lenzi A, Jannini EA (2014) Platelet-derived growth factor regulation of type-5 phosphodiesterase in human and rat penile smooth muscle cells. J Sex Med 11:1675-1684
21. Lin CS (2004) Tissue expression, distribution, and regulation of PDE5. Int J Impot Res 16:S8-S10
22. Montorsi F, Corbin J, Phillips S (2004) Review of phosphodiesterases in the urogenital system: new directions for therapeutic intervention. J Sex Med 1:322-336
23. Wilkins MR, Wharton J, Grimminger F, Ghofrani HA (2008) Phosphodiesterase inhibitors for the treatment of pulmonary hypertension. Eur Respir J 32:198-209
24. Bender AT, Beavo JA (2004) Specific localized expression of cGMP PDEs in Purkinje neurons and macrophages. Neurochem Int 45:853-857
25. Menniti FS, Faraci WS, Schmidt CJ (2006) Phosphodiesterases in the CNS: targets for drug development. Nat Rev Drug Discov 5:660-670
26. Giuliano F, Ückert S, Maggi M, Birder L, Kissel J, Viktrup L (2013) The mechanism of action of phosphodiesterase type 5 inhibitors in the treatment of lower urinary tract symptoms related to benign prostatic hyperplasia. Eur Urol 63:506-516
27. Gresele P, Momi S, Falcinelli E (2011) Anti-platelet therapy: phosphodiesterase inhibitors. Br J Clin Pharmacol 72:634-646
28. Foresta C, Caretta N, Zuccarello D, Poletti A, Biagioli A, Caretti L, Galan A (2008) Expression of the PDE5 enzyme on human retinal tissue: new aspects of PDE5 inhibitors ocular side effects. Eye (Lond) 22:144-149
29. Polak K, Wimpissinger B, Berisha F, Georgopoulos M, Schmetterer L (2003) Effects of sildenafil on retinal blood flow and flicker-induced retinal vasodilatation in healthy subjects. Invest Ophthalmol Vis Sci 44:4872-4876
30. Morelli A, Filippi S, Mancina R, Luconi M, Vignozzi L, Marini M, Orlando C, Vannelli GB, Aversa A, Natali A, Forti G, Giorgi M, Jannini EA, Ledda F, Maggi M (2004) Androgens regulate phosphodiesterase type 5 expression and functional activity in corpora cavernosa. Endocrinology 145:2253-22563
31. Francis SH, Corbin JD (2005) Phosphodiesterase-5 inhibition: the molecular biology of erectile function and dysfunction. Urol Clin North Am 32:419-429
32. Corbin JD, Francis SH (2003) Molecular biology and pharmacology of PDE-5-inhibitor therapy for erectile dysfunction. J Androl 24:S38-S41
33. Corbin JD, Francis SH (2002) Pharmacology of phosphodiesterase-5 inhibitors. Int J Clin Pract 56:453-459
34. Francis SH, Morris GZ, Corbin JD (2008) Molecular mechanisms that could contribute to prolonged effectiveness of PDE5 inhibitors to improve erectile function. Int J Impot Res 20:333-342
35. Blount MA, Beasley A, Zoraghi R, Sekhar KR, Bessay EP, Francis SH, Corbin JD (2004) Binding of tritiated sildenafil, tadalafil, or vardenafil to the phosphodiesterase-5 catalytic site displays potency, specificity, heterogeneity, and cGMP stimulation. Mol Pharmacol 66:144-152
36. Ballard SA, Gingell CJ, Tang K, Turner LA, Price ME, Naylor AM (1998) Effects of sildenafil on the relaxation of human corpus cavernosum tissue in vitro and on the activities of cyclic nucleotide phosphodiesterase isozymes. J Urol 159:2164-2171
37. Turko IV, Ballard SA, Francis SH, Corbin JD (1999) Inhibition of cyclic GMP-binding cyclic GMP-specific phosphodiesterase (type 5) by sildenafil and related compounds. Mol Pharmacol 56:124-130
38. Katz EG, Tan RB, Rittenberg D, Hellstrom WJ (2014) Avanafil for erectile dysfunction in elderly and younger adults: differential pharmacology and clinical utility. Ther Clin Risk Manag 27:701-711
39. Carson CC (2007) Phosphodiesterase type 5 inhibitors: state of the therapeutic class. Urol Clin North Am 34:507-515
40. Gupta M, Kovar A, Meibohm B (2005) The clinical pharmacokinetics of phosphodiesterase-5 inhibitors for erectile dysfunction. J Clin Pharmacol 45:987-1003
41. Bruzziches R, Francomano D, Gareri P, Lenzi A, Aversa A (2013) An update on pharmacological treatment of erectile dysfunction with phosphodi- esterase type 5 inhibitors. Expert Opin Pharmacother 14:1333-1344
42. Kedia GT, Uckert S, Assadi-Pour F, Kuczyk MA, Albrecht K (2013) Avanafil for the treatment of erectile dysfunction: initial data and clinical key properties. Therapeutic Advances Urol 5:35-41
43. Hatzimouratidis K, Hatzichristou DG (2005) A comparative review of the options for treatment of erectile dysfunction: which treatment for which patient? Drugs 65:1621-1650
44. Corona G, Razzoli E, Forti G, Maggi M (2008) The use of phosphodiesterase 5 inhibitors with concomitant medications. J Endocrinol Invest 31:799-808
45. Corona G, Mondaini N, Ungar A, Razzoli E, Rossi A, Fusco F (2011) Phosphodiesterase type 5 (PDE5) inhibitors in erectile dysfunction: the proper drug for the proper patient. J Sex Med 8:3418-3432
46. Jannini EA, DeRogatis LR, Chung E, Brock GB (2012) How to evaluate the efficacy of the phosphodiesterase type 5 inhibitors. J Sex Med 9:26-33
47. Mirone V, Fusco F, Rossi A, Sicuteri R, Montorsi F (2009) Tadalafil and vardenafil vs. sildenafil: a review of patient-preference studies. BJU Int 103:1212-1217
48. Kass DA, Champion HC, Beavo JA (2007) Phosphodiesterase type 5: expanding roles in cardiovascular regulation. Circ Res 101:1084-1095
49. Chrysant SG, Chrysant GS (2012) The pleiotropic effects of phosphodiesterase 5 inhibitors on function and safety in patients with cardiovascular disease and hypertension. J Clin Hyper 14:644-649
50. Goldstein I, Jones LA, Belkoff LH, Karlin GS, Bowden CH, Peterson CA, Trask BA, Day WW (2012) Avanafil for the treatment of erectile dysfunction: a multicenter, randomized, double-blind study in men with diabetes mellitus. Mayo Clin Proc 87:843-852
51. Lugnier C, Schoeffter P, Le Bec A, Strouthou E, Stoclet JC (1986) Selective inhibition of cyclic nucleotide phosphodiesterases of human, bovine and rat aorta. Biochem Pharmacol 35:1743-1751
52. Hamet P, Coquil JF, Bousseau-Lafortune S, Franks DJ, Tremblay J (1984) Cyclic GMP binding and phosphodiesterase: implication for platelet function. Adv Cyclic Nucleotide Protein Phosphorylation Res 16:119-136
53. Reffelman T, Kloner RA (2003) Therapeutic potential of phosphodiesterase 5 inhibition for cardiovascular disease. Circulation 108:239-244
54. Senzaki H, Smith CJ, Juang GJ, Isoda T, Mayer SP, Ohler A, Paolocci N, Tomaselli GF, Hare JM, Kass DA (2001) Cardiac phosphodiesterase 5 (cGMP-specific) modulates b-adrenergic signaling in vivo and is down-regulated in heart failure. FASEB J 15:1718-1726
55. Shenoy P, Agarwal V (2010) Phosphodiesterase inhibitors in the management of autoimmune disease. Autoimmun Rev 9:511-515
56. Kukreja RC, Salloum FD, Das A, Kola S, Ockaili RA, Xi L (2011) Emerging new uses of phosphodiesterase-5 inhibitors in cardiovascular diseases. Exp Clini Cardiol 16:e30-e35
57. Mostafa T (2008) Oral phosphodiesterase type 5 inhibitors: nonerectogenic beneficial uses. J Sex Med 5:2502-2518
58. Diller GP, van Eijl S, Okonko DO, Howard LS, Ali O, Thum T, Wort SJ, Bédard E, Gibbs JS, Bauersachs J, Hobbs AJ, Wilkins MR, Gatzoulis MA, Wharton J (2008) Circulating endothelial progenitor cells in patients with Eisenmenger syndrome and idiopathic pulmonary arterial hypertension. Circulation 117:3020-3030
59. Foresta C, De Toni L, Di Mambro A, Garolla A, Ferlin A, Zuccarello D (2008) The PDE5 inhibitor sildenafil increases circulating endothelial progenitor cells and CXCR4 expression. J Sex Med 6:369-372
60. Kukreja RC (2007) Cardiovascular protection with sildenafil following chronic inhibition of nitric oxide synthase. Br J Clin Pharmacol 150:538-540
61. Das A, Xi L, Kukreja RC (2005) Phosphodiesterase-5 inhibitor sildenafil preconditions adult cardiac myocytes against necrosis and apoptosis. Essential role of nitric oxide signaling. J Biol Chem 280:12944-12955
62. Crescioli C, Sturli N, Sottili M, Bonini P, Lenzi A, Di Luigi L (2013) Insulin-like effect of the phosphodiesterase type 5 inhibitor tadalafil onto male human skeletal muscle cells. J Endocrinol Invest 36:1020-1026
63. Schwartz BG, Levine LA, Comstock G, Stecher VJ, Kloner RA (2012) Cardiac uses of phosphodiesterase-5 inhibitors. J Am Coll Cardiol 59:9-15
64. Guazzi M, Vicenzi M, Arena R, Guazzi MD (2011) PDE5 inhibition with sildenafil improves left ventricular diastolic function, cardiac geometry, and clinical status in patients with stable systolic heart failure: results of a 1-year, prospective, randomized, placebo-controlled study. Circ Heart Fail 4:8-17
65. Giannetta E, Isidori AM, Galea N, Carbone I, Mandosi E, Vizza CD, Naro F, Morano S, Fedele F, Lenzi A (2012) Chronic Inhibition of cGMP phosphodiesterase 5A improves diabetic cardiomyopathy: a randomized, controlled clinical trial using magnetic resonance imaging with myocardial tagging. Circ 125:2323-2333
66. Zhao B, Chen YG (2014) Regulation of TGF-β signal transduction. Scientifica 2014:874065
67. Varga J, Abraham D (2007) Systemic sclerosis: a prototypic multisystem fibrotic disorder. J Clin Investig 117:557-567
68. Guilluy C, Sauzeau V, Rolli-Derkinderen M, Guérin P, Sagan C, Pacaud P, Loirand G (2005) Inhibition of RhoA/Rho kinase pathway is involved in the beneficial effect of sildenafil on pulmonary hypertension. Br J Pharmacol 146:1010-1018
69. Zenzmaier C, Kern J, Sampson N, Heitz M, Plas E, Untergasser G, Berger P (2012) Phosphodiesterase type 5 inhibition reverts prostate fibroblast-to-myofibroblast trans-differentiation. Endocrinology 153:5546-5555
70. Vignozzi L, Gacci M, Cellai I, Morelli A, Maneschi E, Comeglio P, Santi R, Filippi S, Sebastianelli A, Nesi G, Serni S, Carini M, Maggi M (2013) PDE5 inhibitors blunt inflammation in human BPH: a potential mechanism of action for PDE5 inhibitors in LUTS. Prostate 73:1391-1402
71. Bella AJ, Deyoung LX, Al-Numi M, Brock GB (2007) Daily administration of phosphodiesterase type 5 inhibitors for urological and nonurological indications. Eur Urol 52:990-1005
72. Fries R, Shariat K, von Wilmowsky H, Böhm M (2005) Sildenafil in the treatment of Raynaud's phenomenon resistant to vasodilatory therapy. Circulation 112:2980-2985
73. Takeda N, Manabe I (2011) Cellular interplay between cardiomyocytes and nonmyocytes in cardiac remodeling. Int J Inflamm 2011:535241
74. Ross RS (2004) Molecular and mechanical synergy: cross-talk between integrins and growth factor receptors. Cardiovasc Res 63:381-390
75. Sottili M, Cosmi L, Borgogni E, Sarchielli E, Maggi L, Francalanci M, Vannelli GB, Ronconi E, Adorini L, Annunziato F, Romagnani P, Serio M, Crescioli C (2009) Immunomodulatory effects of BXL-01-0029, a less hypercalcemic vitamin D analogue, in human cardiomyocytes and T cells. Exp Cell Res 315:264-273
76. Crescioli C, Squecco R, Cosmi L, Sottili M, Gelmini S, Borgogni E, Sarchielli E, Scolletta S, Francini F, Annunziato F, Vannelli GB, Serio M (2008) Immunosuppression in cardiac graft rejection: a human in vitro model to study the potential use of new immunomodulatory drugs. Exp Cell Res 314:1337-1350
77. Ridker PM, Cushman M, Stampfer MJ, Tracy RP, Hennekens CH (1997) Inflammation, aspirin, and the risk of cardiovascular disease in apparently healty men. N Engl J Med 336:973-979
78. Romagnani P, Crescioli C (2012) CXCL10: a candidate biomarker in transplantation. Clin Chim Acta 413:1364-1373
79. Crescioli C (2013) The role of immunological biomarkers in cardiac rejection. Curr Opin Organ Transplant 18:595-600
80. Scolletta S, Colletti M, Di Luigi L, Crescioli C (2013) Vitamin D receptor agonists target CXCL10: new therapeutic tools for resolution of inflammation. Med Inflamm 2013:876319
81. Penna G, Fibbi B, Amuchastegui S, Cossetti C, Aquilano F, Laverny G, Gacci M, Crescioli C, Maggi M, Adorini L (2009) Human benign prostatic hyperplasia stromal cells as inducers and targets of chronic immuno-mediated inflammation. J Immunol 182:4056-4064
82. Bonecchi R, Bianchi G, Bordignon PP, D'Ambrosio D, Lang R, Borsatti A, Sozzani S, Allavena P, Gray PA, Mantovani A, Sinigaglia F (1998) Differential expression of chemokine receptors and chemotactic responsiveness of type 1 T helper cells (Th1s) and Th2s. J Exp Med 187:129-134
83. Hancock WW, Gao W, Csizmadia V, Faia KL, Shemmeri N, Luster AD (2001) Donor-derived IP-10 initiates development of acute allograft rejection. J Exp Med 193:975-980
84. Crescioli C, Buonamano A, Scolletta S, Sottili M, Francalanci M, Giomarelli P, Biagioli B, Lisi G, Pradella F, Serio M, Romagnani P, Maccherini M (2009) Predictive role of pretransplant serum CXCL10 for cardiac acute rejection. Transplant 87:249-255
85. Yue Y, Gui J, Ai W, Xu W, Xiong S (2011) Direct gene transfer with IP-10 mutant ameliorates mouse CVB3-induced myocarditis by blunting Th1 immune responses. PLoS One 6:e18186
86. Scolletta S, Buonamano A, Sottili M, Giomarelli P, Biagioli B, Vannelli GB, Serio M, Romagnani P, Crescioli C (2012) CXCL10 release in cardiopulmonary bypass: an in vivo and in vitro study. Biomed and Agin Pathol 2:187-194
87. van den Borne P, Quax PHA, Hoefer IE, Pasterkamp G (2014) The multifaceted functions of CXCL10 in cardiovascular disease. BioMed Res Int 2014:893106
88. Salari P, Abdollahi M (2012) Phosphodiesterase inhibitors in inflammatory bowel disease. Expert Opin Investig Drugs 21:261-264
89. Zhuang XD, Long M, Li F, Hu X, Liao XX, Du ZM (2014) PDE5 inhibitor sildenafil in the treatment of heart failure: a meta-analysis of randomized controlled trials. Int J Cardiol 172:581-587
90. Redfield MM, Borlaug BA, Lewis GD, Mohammed SF, Semigran MJ, Lewinter MM, Deswal A, Hernandez AF, Lee KL, Braunwald E, Network The Heart Failure Clinical Research (2012) Phosphdiesterase-5 inhibition to improve clinical status and exercise capacity in diastolic heart failure (RELAX) trial: rationale and design. Circ Heart Fail 5:653-659
91. Degen CV, Bishu K, Zakeri R, Ogut O, Redfield MM, Brozovich FV (2015) The emperor's new clothes: PDE5 and the heart. PLoS One 10:e0118664
92. Takimoto E, Champion HC, Li M, Belardi D, Ren S, Rodriguez ER, Bedja D, Gabrielson KL, Wang Y, Kass DA (2005) Chronic inhibition of cyclic gmp phosphodiesterase 5a prevents and reverses cardiac hypertrophy. Nat Med 11:214-222
93. Nagendran J, Archer SL, Soliman D, Gurtu V, Moudgil R, Haromy A, St Aubin C, Webster L, Rebeyka IM, Ross DB, Light PE, Dyck JR, Michelakis ED (2007) Phosphodiesterase type 5 is highly expressed in the hypertrophied human right ventricle, and acute inhibition of phosphodiesterase type 5 improves contractility. Circulation 116:238-248
94. Shan X, Quaile MP, Monk JK, French B, Cappola TP, Margulies KB (2012) Differential expression of pde5 in failing and nonfailing human myocardium. Circ Heart Fail 5:79-86
95. Pokreisz P, Vandenwijngaert S, Bito V, Van den Bergh A, Lenaerts I, Busch C, Marsboom G, Gheysens O, Vermeersch P, Biesmans L, Liu X, Gillijns H, Pellens M, Van Lommel A, Buys E, Schoonjans L, Vanhaecke J, Verbeken E, Sipido K, Herijgers P, Bloch KD, Janssens SP (2009) Ventricular phosphodiesterase-5 expression is increased in patients with advanced heart failure and contributes to adverse ventricular remodeling after myocardial infarction in mice. Circulation 119:408-416
96. Lu Z, Xu X, Hu X, Lee S, Traverse JH, Zhu G, Fassett J, Tao Y, Zhang P, dos Remedios C, Pritzker M, Hall JL, Garry DJ, Chen Y (2010) Oxidative stress regulates left ventricular pde5 expression in the failing heart. Circulation 121:1474-1483
97. Borlaug BA, Paulus WJ (2011) Heart failure with preserved ejection fraction: pathophysiology, diagnosis, and treatment. Eur Heart J 32:670-679